High-dose cytarabine for consolidation therapy of acute myeloid leukemia in first complete remission

• 作 者: 李茜;陈洁平;
• 机 构: 重庆西南医院血液科
• 出 处: 第十五届全国实验血液学学术会议
• 发表日期: 2015年期

　　Background New evidence has questioned the role of high-dose cytarabine (HDAC) in consolidation therapy of acute myeloid leukemia (AML) in first complete remission (CR1).We performed a meta-analysis to clarify the question.Methods An extensive literature search was conducted to identify randomized controlled trials (RCTs) comparing HDAC with other therapies for AML in CR1 without donor.The pooled hazard ratios (HRs) for overall survival (OS) and relapse-free survival (RFS), and the pooled odds ratio (ORs) for treatment related mortality (TRM) and toxicities were calculated.